Recent efforts focus on transcriptional profiling for identifying therapeutic targets and subtypes [10] with studies defining SCLC subtypes by differential expression of transcriptional factors, including achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1) [11], POU class 2 homeobox 3 (POU2F3) [12], and yes-associated protein 1 (YAP1) [13]. This evidence concerns the gene ASCL1 and small cell lung carcinoma.